APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Anca Vasculitis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anca Vasculitis Drug Market Outlook and Growth Opportunities 2026

Report ID 173963380419 December 2025192 pages

Choose your research edition.

Industry ResearchAnca Vasculitis Drug Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Anca Vasculitis Drug Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Anca Vasculitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anca Vasculitis Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Anca Vasculitis Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Anca Vasculitis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anca Vasculitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anca Vasculitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anca Vasculitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anca Vasculitis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anca Vasculitis Drug market include ChemoCentryx, Inc., Kineta, Inc. and GlaxoSmithKline plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anca Vasculitis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anca Vasculitis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anca Vasculitis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anca Vasculitis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Anca Vasculitis Drug Segment by Company

ChemoCentryx, Inc.

Kineta, Inc.

GlaxoSmithKline plc

Anca Vasculitis Drug Segment by Type

Dalazatide

Belimumab

CCX-168

CCX-1378

Others

Anca Vasculitis Drug Segment by Application

Hospital

Clinic

Others

Anca Vasculitis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Anca Vasculitis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anca Vasculitis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anca Vasculitis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Anca Vasculitis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anca Vasculitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anca Vasculitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anca Vasculitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anca Vasculitis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anca Vasculitis Drug industry.

Chapter 3: Detailed analysis of Anca Vasculitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anca Vasculitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anca Vasculitis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anca Vasculitis Drug Industry Trends Table 2. Anca Vasculitis Drug Industry Drivers Table 3. Anca Vasculitis Drug Industry Opportunities and Challenges Table 4. Anca Vasculitis Drug Industry Restraints Table 5. Global Anca Vasculitis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anca Vasculitis Drug Revenue Share by Company (2021-2026) Table 7. Global Anca Vasculitis Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Anca Vasculitis Drug Sales Volume Share by Company (2021-2026) Table 9. Global Anca Vasculitis Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Anca Vasculitis Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anca Vasculitis Drug Key Company Manufacturing Base & Headquarters Table 12. Global Anca Vasculitis Drug Company, Product Type & Application Table 13. Global Anca Vasculitis Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anca Vasculitis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Dalazatide Table 18. Significant Companies of Belimumab Table 19. Significant Companies of CCX-168 Table 20. Significant Companies of CCX-1378 Table 21. Significant Companies of Others Table 22. Global Anca Vasculitis Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Anca Vasculitis Drug Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Anca Vasculitis Drug Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Anca Vasculitis Drug Sales Volume Share by Type (2021-2026) Table 26. Global Anca Vasculitis Drug Sales Volume Share by Type (2027-2032) Table 27. Global Anca Vasculitis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Anca Vasculitis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Anca Vasculitis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Anca Vasculitis Drug Sales Value Share by Type (2021-2026) Table 31. Global Anca Vasculitis Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Significant Companies of Others Table 35. Global Anca Vasculitis Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Anca Vasculitis Drug Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Anca Vasculitis Drug Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Anca Vasculitis Drug Sales Volume Share by Application (2021-2026) Table 39. Global Anca Vasculitis Drug Sales Volume Share by Application (2027-2032) Table 40. Global Anca Vasculitis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Anca Vasculitis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Anca Vasculitis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Anca Vasculitis Drug Sales Value Share by Application (2021-2026) Table 44. Global Anca Vasculitis Drug Sales Value Share by Application (2027-2032) Table 45. Global Anca Vasculitis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Anca Vasculitis Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Anca Vasculitis Drug Sales Market Share by Region (2021-2026) Table 48. Global Anca Vasculitis Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Anca Vasculitis Drug Sales Market Share by Region (2027-2032) Table 50. Global Anca Vasculitis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Anca Vasculitis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Anca Vasculitis Drug Sales Value Share by Region (2021-2026) Table 53. Global Anca Vasculitis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Anca Vasculitis Drug Sales Value Share by Region (2027-2032) Table 55. Global Anca Vasculitis Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Anca Vasculitis Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Anca Vasculitis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Anca Vasculitis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Anca Vasculitis Drug Sales by Country (2021-2026) & (K Units) Table 60. Global Anca Vasculitis Drug Sales Market Share by Country (2021-2026) Table 61. Global Anca Vasculitis Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Anca Vasculitis Drug Sales Market Share by Country (2027-2032) Table 63. Global Anca Vasculitis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Anca Vasculitis Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Anca Vasculitis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Anca Vasculitis Drug Sales Value Market Share by Country (2027-2032) Table 67. ChemoCentryx, Inc. Company Information Table 68. ChemoCentryx, Inc. Business Overview Table 69. ChemoCentryx, Inc. Anca Vasculitis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. ChemoCentryx, Inc. Anca Vasculitis Drug Product Portfolio Table 71. ChemoCentryx, Inc. Recent Development Table 72. Kineta, Inc. Company Information Table 73. Kineta, Inc. Business Overview Table 74. Kineta, Inc. Anca Vasculitis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Kineta, Inc. Anca Vasculitis Drug Product Portfolio Table 76. Kineta, Inc. Recent Development Table 77. GlaxoSmithKline plc Company Information Table 78. GlaxoSmithKline plc Business Overview Table 79. GlaxoSmithKline plc Anca Vasculitis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. GlaxoSmithKline plc Anca Vasculitis Drug Product Portfolio Table 81. GlaxoSmithKline plc Recent Development Table 82. Key Raw Materials Table 83. Raw Materials Key Suppliers Table 84. Anca Vasculitis Drug Distributors List Table 85. Anca Vasculitis Drug Customers List Table 86. Research Programs/Design for This Report Table 87. Authors List of This Report Table 88. Secondary Sources Table 89. Primary Sources List of Figures Figure 1. Anca Vasculitis Drug Product Image Figure 2. Global Anca Vasculitis Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anca Vasculitis Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anca Vasculitis Drug Sales (2021-2032) & (K Units) Figure 5. Global Anca Vasculitis Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Anca Vasculitis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Dalazatide Image Figure 10. Belimumab Image Figure 11. CCX-168 Image Figure 12. CCX-1378 Image Figure 13. Others Image Figure 14. Global Anca Vasculitis Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Anca Vasculitis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Anca Vasculitis Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Anca Vasculitis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Anca Vasculitis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Anca Vasculitis Drug Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Anca Vasculitis Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Anca Vasculitis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Anca Vasculitis Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Anca Vasculitis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Anca Vasculitis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Anca Vasculitis Drug Sales Value Share by Application (2021-2032) Figure 29. Global Anca Vasculitis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Anca Vasculitis Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Anca Vasculitis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Anca Vasculitis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Anca Vasculitis Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Anca Vasculitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Anca Vasculitis Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Anca Vasculitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Anca Vasculitis Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Anca Vasculitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Anca Vasculitis Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Anca Vasculitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Anca Vasculitis Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Anca Vasculitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Anca Vasculitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Anca Vasculitis Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Anca Vasculitis Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Dalazatide
  • Belimumab
  • CCX-168
  • CCX-1378
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • ChemoCentryx, Inc.
  • Kineta, Inc.
  • GlaxoSmithKline plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anca Vasculitis Drug Sales Value (2021-2032)
  4. 1.2.2 Global Anca Vasculitis Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Anca Vasculitis Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anca Vasculitis Drug Market Dynamics
  1. 2.1 Anca Vasculitis Drug Industry Trends
  2. 2.2 Anca Vasculitis Drug Industry Drivers
  3. 2.3 Anca Vasculitis Drug Industry Opportunities and Challenges
  4. 2.4 Anca Vasculitis Drug Industry Restraints
3 Anca Vasculitis Drug Market by Company
  1. 3.1 Global Anca Vasculitis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Anca Vasculitis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Anca Vasculitis Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Anca Vasculitis Drug Average Price by Company (2021-2026)
  5. 3.5 Global Anca Vasculitis Drug Company Ranking (2024-2026)
  6. 3.6 Global Anca Vasculitis Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Anca Vasculitis Drug Company Product Type and Application
  8. 3.8 Global Anca Vasculitis Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anca Vasculitis Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anca Vasculitis Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anca Vasculitis Drug Market by Type
  1. 4.1 Anca Vasculitis Drug Type Introduction
  2. 4.1.1 Dalazatide
  3. 4.1.2 Belimumab
  4. 4.1.3 CCX-168
  5. 4.1.4 CCX-1378
  6. 4.1.5 Others
  7. 4.2 Global Anca Vasculitis Drug Sales Volume by Type
  8. 4.2.1 Global Anca Vasculitis Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Anca Vasculitis Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Anca Vasculitis Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Anca Vasculitis Drug Sales Value by Type
  12. 4.3.1 Global Anca Vasculitis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Anca Vasculitis Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Anca Vasculitis Drug Sales Value Share by Type (2021-2032)
5 Anca Vasculitis Drug Market by Application
  1. 5.1 Anca Vasculitis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Anca Vasculitis Drug Sales Volume by Application
  6. 5.2.1 Global Anca Vasculitis Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anca Vasculitis Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Anca Vasculitis Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Anca Vasculitis Drug Sales Value by Application
  10. 5.3.1 Global Anca Vasculitis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Anca Vasculitis Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Anca Vasculitis Drug Sales Value Share by Application (2021-2032)
6 Anca Vasculitis Drug Regional Sales and Value Analysis
  1. 6.1 Global Anca Vasculitis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anca Vasculitis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Anca Vasculitis Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Anca Vasculitis Drug Sales by Region (2027-2032)
  5. 6.3 Global Anca Vasculitis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anca Vasculitis Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anca Vasculitis Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anca Vasculitis Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Anca Vasculitis Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anca Vasculitis Drug Sales Value (2021-2032)
  12. 6.6.2 North America Anca Vasculitis Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anca Vasculitis Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Anca Vasculitis Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anca Vasculitis Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anca Vasculitis Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anca Vasculitis Drug Sales Value (2021-2032)
  21. 6.9.2 South America Anca Vasculitis Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anca Vasculitis Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anca Vasculitis Drug Sales Value Share by Country, 2025 VS 2032
7 Anca Vasculitis Drug Country-level Sales and Value Analysis
  1. 7.1 Global Anca Vasculitis Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anca Vasculitis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anca Vasculitis Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Anca Vasculitis Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Anca Vasculitis Drug Sales by Country (2027-2032)
  6. 7.4 Global Anca Vasculitis Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anca Vasculitis Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anca Vasculitis Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anca Vasculitis Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anca Vasculitis Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anca Vasculitis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ChemoCentryx, Inc.
  2. 8.1.1 ChemoCentryx, Inc. Company Information
  3. 8.1.2 ChemoCentryx, Inc. Business Overview
  4. 8.1.3 ChemoCentryx, Inc. Anca Vasculitis Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 ChemoCentryx, Inc. Anca Vasculitis Drug Product Portfolio
  6. 8.1.5 ChemoCentryx, Inc. Recent Developments
  7. 8.2 Kineta, Inc.
  8. 8.2.1 Kineta, Inc. Company Information
  9. 8.2.2 Kineta, Inc. Business Overview
  10. 8.2.3 Kineta, Inc. Anca Vasculitis Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Kineta, Inc. Anca Vasculitis Drug Product Portfolio
  12. 8.2.5 Kineta, Inc. Recent Developments
  13. 8.3 GlaxoSmithKline plc
  14. 8.3.1 GlaxoSmithKline plc Company Information
  15. 8.3.2 GlaxoSmithKline plc Business Overview
  16. 8.3.3 GlaxoSmithKline plc Anca Vasculitis Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline plc Anca Vasculitis Drug Product Portfolio
  18. 8.3.5 GlaxoSmithKline plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anca Vasculitis Drug Value Chain Analysis
  2. 9.1.1 Anca Vasculitis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anca Vasculitis Drug Sales Mode & Process
  6. 9.2 Anca Vasculitis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anca Vasculitis Drug Distributors
  9. 9.2.3 Anca Vasculitis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst